DIA
Drug Information Association Logo
« Back to Listing

Communicating Clinical Trial Results: Targeting the Patient Audience

Track:
Medical Communication, Medical Writing, and Medical Science Liaison

Day & Time:
June 17, 8:00AM - 9:30AM (Pacific Standard Time)

Session Number:
209

Room Number:
31AB

Level:
Intermediate

Type:
Session

Title:
Communicating Clinical Trial Results: Targeting the Patient Audience

Chair(s):
David B. Clemow, PhD
Senior Clinical Research Scientist
Lilly USA, LLC, United States

Description:
This session will describe current venues where drug development organizations communicate clinical trial results to patients, how to best communicate, and the importance of meeting patients' needs for them and the drug development organization.

This session has been developed by the DIA Medical Writing, Patient Engagement, Medical Communications, and Clinical Trial Disclosure Communities.

Learning Objective(s):
Describe current venues/channels where drug development organizations communicate clinical trial results to the patient; Illustrate how to best compose medical communications to meet patient needs; Discuss appropriate writing levels, important content components, and key considerations; Summarize the importance of meeting patient audience needs for them and the drug development organization.

Presentation(s) & Speaker(s):
Communicating Medical Information
David Leventhal
Director, Clinical Innovation, Worldwide Research and Development
Pfizer Inc, United States

Patient Perspective on Communication
Colleen Zak, BSN
Founder / President
ARPKD/CHF Alliance, United States

Communicating Through Clinical Trial Disclosures
Barbara Godlew, RN
President
The FAIRE Company, LLC, United States

Communicating Through Advertising/Promotion
David B. Clemow, PhD
Senior Clinical Research Scientist
Lilly USA, LLC, United States